Ezetimibe for Hypercholesterolemia
Ezetimibe 10 mg daily should be added to maximally tolerated statin therapy when LDL-C remains elevated above goal, particularly in patients with atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk who have not achieved adequate LDL-C reduction with statin monotherapy. 1, 2
FDA-Approved Indications
Ezetimibe is indicated for 2:
- Primary hyperlipidemia (including heterozygous familial hypercholesterolemia): In combination with a statin, or as monotherapy when additional LDL-C lowering therapy is not possible
- Pediatric HeFH: In combination with a statin for patients ≥10 years of age
- Mixed hyperlipidemia: In combination with fenofibrate
- Homozygous familial hypercholesterolemia (HoFH): In combination with a statin and other LDL-C lowering therapies (adults and pediatric patients ≥10 years)
- Homozygous familial sitosterolemia: As monotherapy for patients ≥9 years of age
Dosing
Standard dose: 10 mg orally once daily, with or without food 1, 2
Critical timing consideration: Administer ezetimibe either ≥2 hours before or ≥4 hours after bile acid sequestrants if used in combination 1, 2
When to Add Ezetimibe: Risk-Stratified Approach
The 2022 ACC Expert Consensus and multiple international guidelines provide clear thresholds 3, 1:
Very High Cardiovascular Risk Patients
- Add ezetimibe when LDL-C remains ≥70 mg/dL (1.8 mmol/L) on maximally tolerated statin 3
- European guidelines recommend combination therapy if LDL-C goal of <55 mg/dL (1.4 mmol/L) is not achieved with maximum tolerated statin dose 3
High Cardiovascular Risk Patients
- Consider adding ezetimibe when LDL-C remains ≥135 mg/dL (3.5 mmol/L) despite statin therapy 3
Primary Prevention
- Kaiser Permanente guidelines suggest adding ezetimibe if maximum tolerated statin does not achieve >40% reduction in non-HDL cholesterol from baseline after 3 months 3
Expected LDL-C Reduction
- Monotherapy: 18% reduction 1
- Combined with statin: Additional 17-25% incremental reduction beyond statin alone 1, 4
- This complementary mechanism (blocking intestinal cholesterol absorption while statins inhibit hepatic synthesis) produces synergistic effects 5, 6
Contraindications
Absolute contraindication: History of hypersensitivity to ezetimibe 1, 2
When combined with other agents: Ezetimibe is contraindicated in patients for whom the co-administered statin, fenofibrate, or other LDL-C lowering therapy is contraindicated 2
Warnings and Precautions
Hepatic Monitoring
- Not recommended in moderate to severe hepatic impairment 1
- Monitor liver transaminases before and during treatment, particularly when combined with statins 1, 2
- Consider withdrawal if ALT or AST ≥3× ULN persist 2
Skeletal Muscle Effects
- Ezetimibe may cause myopathy and rhabdomyolysis, particularly when combined with statins 2
- Most post-marketing reports of rhabdomyolysis occurred in patients taking statins or fibrates concurrently 2
- Discontinue ezetimibe if myopathy is suspected 2
Monitoring Recommendations
- Assess LDL-C as early as 4 weeks after initiating ezetimibe 2
- Monitor liver enzymes as clinically indicated, especially when combined with statins 1, 2
- Watch for signs/symptoms of myopathy (muscle pain, weakness) 2
Adverse Effects
Common adverse reactions (≥2% incidence) 2:
- Upper respiratory tract infection
- Diarrhea
- Arthralgia
- Sinusitis
- Pain in extremities
- Fatigue
When combined with statins: Nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea 1
The safety profile is generally excellent and comparable to placebo in long-term studies up to 2 years 7
Drug Interactions
Significant interactions 1:
- Cyclosporine: Use with caution
- Fibrates: Monitor closely
- Bile acid sequestrants: Administer ezetimibe ≥2 hours before or ≥4 hours after
Minimal CYP450 interactions: Because ezetimibe is eliminated primarily by glucuronidation rather than CYP oxidation, it has minimal drug interactions involving the CYP enzyme system 5
Cardiovascular Outcomes Evidence
IMPROVE-IT trial: Adding ezetimibe to moderate-intensity statin therapy in patients with recent acute coronary syndrome resulted in incremental LDL-C lowering and reduced the composite endpoint of CV death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke over median 6-year follow-up 1
SHARP trial: Simvastatin plus ezetimibe reduced major atherosclerotic cardiovascular events compared with placebo in patients with chronic kidney disease over median 4.9-year follow-up 1
Pregnancy and Lactation
Avoid use during pregnancy: No safety data in humans 1
Discontinue when pregnancy is recognized unless benefits clearly outweigh potential fetal risks 2
Clinical Pearls
- Generic availability makes ezetimibe cost-effective 1
- Generally well tolerated with excellent long-term safety profile 7
- In patients on triple therapy (statin + ezetimibe + PCSK9 inhibitor), deprescribing ezetimibe typically increases LDL-C but may remain below treatment intensification thresholds in high-risk patients 8
- The combination allows achievement of aggressive LDL-C goals recommended in current guidelines, with 71.5% of patients reaching NCEP goals versus only 18.9% with statin alone 4